Download PDF
Semin Thromb Hemost 2004; 30(1): 127-136
DOI: 10.1055/s-2004-822977
Copyright © 2004 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA.

Mechanisms of Thrombospondin-1-Mediated Metastasis and Angiogenesis

Irene Sargiannidou1 , Cuie Qiu2 , George P. Tuszynski3
  • 1Adjunct instructor, Department of Pathology and Laboratory Medicine, Drexel University College of Medicine, Philadelphia, Pennsylvania
  • 2Department of Pharmacology and Physiology, Drexel University College of Medicine, Philadelphia, Pennsylvania
  • 3Center for Neurovirology and Cancer Biology, Temple University, Philadelphia, Pennsylvania
Further Information

Publication History

Publication Date:
22 March 2004 (online)

    Permissions and Reprints

The major route of tumor spread is through the bloodstream. Once in circulation, the tumor cells aggregate in clumps with platelets, which enhances the tumor cell survival. The tumor emboli will then adhere to the endothelium and by the release of proteases extravasation of the cells will occur. One of the platelet-secreted proteins is thrombospondin-1. In this article, thrombospondin-1 will be described as a modulator of angiogenesis through its role in regulating endothelial cell apoptosis, protease expression, and vascular endothelial growth factor expression. We hope to convey the idea that activity of thrombospondin-1 in tumor progression is dependent upon its interaction with several host- and tumor-associated proteins.

KEYWORDS

Thrombospondin-1 - metastasis - angiogenesis - proteases - vascular endothelial growth factor

REFERENCES

  • 1 Recamier J C. L'Histoire de la Même Maladie. Vol 2 Paris; Gabon 1829: 731-737
    Google Scholar
  • 2 Paget S. The distribution of secondary growths in cancer of the breast.  Lancet. 1889;  1 571-573
    PubMedGoogle Scholar
  • 3 Billroth T. Lectures on Surgical Pathology and Therapeutics: A Handbook for Students and Practitioners. London; New Syndenham Society 1878: 355
    Google Scholar
  • 4 Trousseau A. Clinique Médicale de L'Hôtel de Paris. Vol 3 Paris; Balliere 1865: 654-656
    Google Scholar
  • 5 Bick R L. Coagulation abnormalities in malignancy: a review.  Semin Thromb Hemost. 1992;  18 353-372
    Article in Thieme ConnectPubMedGoogle Scholar
  • 6 Falanga A, Gordon S G. Isolation and characterization of cancer procoagulant: a cysteine proteinase from malignant tissue.  Biochemistry. 1985;  24 5558-5567
    CrossrefPubMedGoogle Scholar
  • 7 Tohgo A, Tanaka N, Ashida S, Ogawa H. Platelet-aggregating activities of metastasizing tumor cells. II. Variety of the aggregation mechanisms.  Invasion Metastasis. 1984;  4 134-145
    PubMedGoogle Scholar
  • 8 Gasic G J, Gasic T B, Stewart C C. Antimetastatic effects associated with platelet reduction.  Proc Natl Acad Sci USA. 1968;  61 46-52
    PubMedGoogle Scholar
  • 9 Karpatkin S, Pearlstein E, Ambrogio C, Coller B S. Role of adhesive proteins in platelet tumor interaction in vitro and metastasis formation in vivo.  J Clin Invest. 1988;  81 1012-1019
    CrossrefPubMedGoogle Scholar
  • 10 Honn K V, Tang D G, Chen Y Q. Platelets and cancer metastasis: more than an epiphenomenon.  Semin Thromb Hemost. 1992;  18 392-415
    PubMedGoogle Scholar
  • 11 Honn K V, Cicone B, Skoff A. Prostacyclin: a potent antimetastatic agent.  Science. 1981;  212 1270-1272
    PubMedGoogle Scholar
  • 12 Marnett L J. Aspirin and the potential role of prostaglandins in colon cancer.  Cancer Res. 1992;  52 5575-5589
    PubMedGoogle Scholar
  • 13 Tuszynski G P, Gasic T B, Rothman V L, Knudsen K A, Gasic G J. Thrombospondin, a potentiator of tumor cell metastasis.  Cancer Res. 1987;  47 4130-4133
    PubMedGoogle Scholar
  • 14 Tuszynski G P, Rothman V L, Murphy A, Siegler K, Knudsen K A. Thrombospondin promotes platelet aggregation.  Blood. 1988;  72 109-115
    PubMedGoogle Scholar
  • 15 Hogg P J, Stenflo J, Mosher D F. Thrombospondin is a slow tight-binding inhibitor of plasmin.  Biochemistry. 1992;  31 265-269
    CrossrefPubMedGoogle Scholar
  • 16 Lawler J. Thrombospondin-1 as an endogenous inhibitor of angiogenesis and tumor growth.  J Cell Mol Med. 2002;  6 1-12
    PubMedGoogle Scholar
  • 17 Baenziger N L, Brodie G N, Majerus P W. A thrombin-sensitive protein of human platelet membranes.  Proc Natl Acad Sci USA. 1971;  68 240-243
    PubMedGoogle Scholar
  • 18 DiPietro L A, Polverini P J. Angiogenic macrophages produce the angiogenic inhibitor thrombospondin 1.  Am J Pathol. 1993;  143 678-684
    PubMedGoogle Scholar
  • 19 Reed M J, Puolakkainen P, Lane T F, Dickerson D, Bornstein P, Sage E H. Differential expression of SPARC and thrombospondin 1 in wound repair: immunolocalization and in situ hybridization.  J Histochem Cytochem. 1993;  41 1467-1477
    PubMedGoogle Scholar
  • 20 Adolph K W. A thrombospondin homologue in Drosophila melanogaster: cDNA and protein structure.  Gene. 2001;  269 177-184
    CrossrefPubMedGoogle Scholar
  • 21 Tolsma S S, Volpert O V, Good D J, Frazier W A, Polverini P J, Bouck N. Peptides derived from two separate domains of the matrix protein thrombospondin-1 have anti-angiogenic activity.  J Cell Biol. 1993;  122 497-511
    CrossrefPubMedGoogle Scholar
  • 22 Dawson D W, Volpert O V, Pearce S F et al.. Three distinct D-amino acid substitutions confer potent antiangiogenic activity on an inactive peptide derived from a thrombospondin-1 type 1 repeat.  Mol Pharmacol. 1999;  55 332-338
    PubMedGoogle Scholar
  • 23 Reiher F K, Volpert O V, Jimenez B et al.. Inhibition of tumor growth by systemic treatment with thrombospondin-1 peptide mimetics.  Int J Cancer. 2002;  98 682-689
    CrossrefPubMedGoogle Scholar
  • 24 Iruela-Arispe M L, Lombardo M, Krutzsch H C, Lawler J, Roberts D D. Inhibition of angiogenesis by thrombospondin-1 is mediated by 2 independent regions within the type 1 repeats.  Circulation. 1999;  100 1423-1431
    PubMedGoogle Scholar
  • 25 Kanda S, Shono T, Tomasini-Johansson B, Klint P, Saito Y. Role of thrombospondin-1-derived peptide, 4N1K, in FGF-2-induced angiogenesis.  Exp Cell Res. 1999;  252 262-272
    CrossrefPubMedGoogle Scholar
  • 26 Taraboletti G, Morbidelli L, Donnini S et al.. The heparin binding 25 kDa fragment of thrombospondin-1 promotes angiogenesis and modulates gelatinase and TIMP-2 production in endothelial cells.  FASEB J. 2000;  14 1674-1676
    PubMedGoogle Scholar
  • 27 Ferrari do Outeiro-Bernstein M A, Nunes S S, Andrade A C, Alves T R, Legrand C, Morandi V. A recombinant NH(2)-terminal heparin-binding domain of the adhesive glycoprotein, thrombospondin-1, promotes endothelial tube formation and cell survival: a possible role for syndecan-4 proteoglycan.  Matrix Biol. 2002;  21 311-324
    CrossrefPubMedGoogle Scholar
  • 28 Guo N, Krutzsch H C, Inman J K, Roberts D D. Thrombospondin 1 and type I repeat peptides of thrombospondin 1 specifically induce apoptosis of endothelial cells.  Cancer Res. 1997;  57 1735-1742
    PubMedGoogle Scholar
  • 29 Dawson D W, Pearce S F, Zhong R, Silverstein R L, Frazier W A, Bouck N P. CD36 mediates the in vitro inhibitory effects of thrombospondin-1 on endothelial cells.  J Cell Biol. 1997;  138 707-717
    CrossrefPubMedGoogle Scholar
  • 30 Jimenez B, Volpert O V, Crawford S E, Febbraio M, Silverstein R L, Bouck N. Signals leading to apoptosis-dependent inhibition of neovascularization by thrombospondin-1.  Nat Med. 2000;  6 41-48
    PubMedGoogle Scholar
  • 31 Jimenez B, Volpert O V, Reiher F et al.. c-Jun N-terminal kinase activation is required for the inhibition of neovascularization by thrombospondin-1.  Oncogene. 2001;  20 3443-3448
    CrossrefPubMedGoogle Scholar
  • 32 Volpert O V, Zaichuk T, Zhou W et al.. Inducer-stimulated Fas targets activated endothelium for destruction by anti-angiogenic thrombospondin-1 and pigment epithelium-derived factor.  Nat Med. 2002;  8 349-357
    PubMedGoogle Scholar
  • 33 Freyberg M A, Kaiser D, Graf R, Vischer P, Friedl P. Integrin-associated protein and thrombospondin-1 as endothelial mechanosensitive death mediators.  Biochem Biophys Res Commun. 2000;  271 584-588
    CrossrefPubMedGoogle Scholar
  • 34 Freyberg M A, Kaiser D, Graf R, Buttenbender J, Friedl P. Proatherogenic flow conditions initiate endothelial apoptosis via thrombospondin-1 and the integrin-associated protein.  Biochem Biophys Res Commun. 2001;  286 141-149
    CrossrefPubMedGoogle Scholar
  • 35 Stromblad S, Becker J C, Yebra M, Brooks P C, Cheresh D A. Suppression of p53 activity and p21WAF1/CIP1 expression by vascular cell integrin alphaVbeta3 during angiogenesis.  J Clin Invest. 1996;  98 426-433
    PubMedGoogle Scholar
  • 36 Hogg P J. Thrombospondin 1 as an enzyme inhibitor.  Thromb Haemost. 1994;  72 787-792
    PubMedGoogle Scholar
  • 37 Albo D, Arnoletti J P, Castiglioni A et al.. Thrombospondin (TSP) and transforming growth factor beta 1 (TGF-beta) promote human A549 lung carcinoma cell plasminogen activator inhibitor type 1 (PAI-1) production and stimulate tumor cell attachment in vitro.  Biochem Biophys Res Commun. 1994;  203 857-865
    CrossrefPubMedGoogle Scholar
  • 38 Arnoletti J P, Albo D, Granick M S et al.. Thrombospondin and transforming growth factor-beta 1 increase expression of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in human MDA-MB-231 breast cancer cells.  Cancer. 1995;  76 998-1005
    PubMedGoogle Scholar
  • 39 Blasi F. Urokinase and urokinase receptor: a paracrine/autocrine system regulating cell migration and invasiveness.  Bioessays. 1993;  15 105-111
    CrossrefPubMedGoogle Scholar
  • 40 Albo D, Berger D H, Wang T N, Hu X, Rothman V, Tuszynski G P. Thrombospondin-1 and transforming growth factor-beta l promote breast tumor cell invasion through up-regulation of the plasminogen/plasmin system.  Surgery. 1997;  122 493-449 , discussion 499-500
    CrossrefPubMedGoogle Scholar
  • 41 Albo D, Berger D H, Tuszynski G P. The effect of thrombospondin-1 and TGF-beta 1 on pancreatic cancer cell invasion.  J Surg Res. 1998;  76 86-90
    CrossrefPubMedGoogle Scholar
  • 42 Albo D, Rothman V L, Roberts D D, Tuszynski G P. Tumour cell thrombospondin-1 regulates tumour cell adhesion and invasion through the urokinase plasminogen activator receptor.  Br J Cancer. 2000;  83 298-306
    CrossrefPubMedGoogle Scholar
  • 43 John A, Tuszynski G. The role of matrix metalloproteinases in tumor angiogenesis and tumor metastasis.  Pathol Oncol Res. 2001;  7 14-23
    PubMedGoogle Scholar
  • 44 Qian X, Wang T N, Rothman V L, Nicosia R F, Tuszynski G P. Thrombospondin-1 modulates angiogenesis in vitro by up-regulation of matrix metalloproteinase-9 in endothelial cells.  Exp Cell Res. 1997;  235 403-412
    CrossrefPubMedGoogle Scholar
  • 45 Bein K, Simons M. Thrombospondin type 1 repeats interact with matrix metalloproteinase 2. Regulation of metalloproteinase activity.  J Biol Chem. 2000;  275 32167-32173
    CrossrefPubMedGoogle Scholar
  • 46 Rodriguez-Manzaneque J C, Lane T F, Ortega M A, Hynes R O, Lawler J, Iruela-Arispe M L. Thrombospondin-1 suppresses spontaneous tumor growth and inhibits activation of matrix metalloproteinase-9 and mobilization of vascular endothelial growth factor.  Proc Natl Acad Sci USA. 2001;  98 12485-12490
    CrossrefPubMedGoogle Scholar
  • 47 Dvorak H F, Brown L F, Detmar M, Dvorak A M. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis.  Am J Pathol. 1995;  146 1029-1039
    PubMedGoogle Scholar
  • 48 Kawahara N, Ono M, Taguchi K et al.. Enhanced expression of thrombospondin-1 and hypovascularity in human cholangiocarcinoma.  Hepatology. 1998;  28 1512-1517
    CrossrefPubMedGoogle Scholar
  • 49 de Fraipont F, El Atifi M, Gicquel C, Bertagna X, Chambaz E M, Feige J J. Expression of the angiogenesis markers vascular endothelial growth factor-A, thrombospondin-1, and platelet-derived endothelial cell growth factor in human sporadic adrenocortical tumors: correlation with genotypic alterations.  J Clin Endocrinol Metab. 2000;  85 4734-4741
    CrossrefPubMedGoogle Scholar
  • 50 Kang D H, Anderson S, Kim Y G et al.. Impaired angiogenesis in the aging kidney: vascular endothelial growth factor and thrombospondin-1 in renal disease.  Am J Kidney Dis. 2001;  37 601-611
    PubMedGoogle Scholar
  • 51 Kang D H, Joly A H, Oh S W et al.. Impaired angiogenesis in the remnant kidney model: I. Potential role of vascular endothelial growth factor and thrombospondin-1.  J Am Soc Nephrol. 2001;  12 1434-1447
    PubMedGoogle Scholar
  • 52 Tanaka K, Sonoo H, Kurebayashi J et al.. Inhibition of infiltration and angiogenesis by thrombospondin-1 in papillary thyroid carcinoma.  Clin Cancer Res. 2002;  8 1125-1131
    PubMedGoogle Scholar
  • 53 Tan X J, Lang J H, Liu D Y, Shen K, Leng J H, Zhu L. Expression of vascular endothelial growth factor and thrombospondin-1 mRNA in patients with endometriosis.  Fertil Steril. 2002;  78 148-153
    CrossrefPubMedGoogle Scholar
  • 54 Dameron K M, Volpert O V, Tainsky M A, Bouck N. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1.  Science. 1994;  265 1582-1584
    CrossrefPubMedGoogle Scholar
  • 55 Kieser A, Weich H A, Brandner G, Marme D, Kolch W. Mutant p53 potentiates protein kinase C induction of vascular endothelial growth factor expression.  Oncogene. 1994;  9 963-969
    PubMedGoogle Scholar
  • 56 Mukhopadhyay D, Tsiokas L, Sukhatme V P. Wild-type p53 and v-Src exert opposing influences on human vascular endothelial growth factor gene expression.  Cancer Res. 1995;  55 6161-6165
    PubMedGoogle Scholar
  • 57 Grossfeld G D, Ginsberg D A, Stein J P et al.. Thrombospondin-1 expression in bladder cancer: association with p53 alterations, tumor angiogenesis, and tumor progression.  J Natl Cancer Inst. 1997;  89 219-227
    CrossrefPubMedGoogle Scholar
  • 58 Fontanini G, Boldrini L, Calcinai A et al.. Thrombospondins I and II messenger RNA expression in lung carcinoma: relationship with p53 alterations, angiogenic growth factors, and vascular density.  Clin Cancer Res. 1999;  5 155-161
    PubMedGoogle Scholar
  • 59 Kwak C, Jin R J, Lee C, Park M S, Lee S E. Thrombospondin-1, vascular endothelial growth factor expression and their relationship with p53 status in prostate cancer and benign prostatic hyperplasia.  BJU Int. 2002;  89 303-309
    CrossrefPubMedGoogle Scholar
  • 60 Chen H, Herndon M E, Lawler J. The cell biology of thrombospondin-1.  Matrix Biol. 2000;  19 597-614
    CrossrefPubMedGoogle Scholar
  • 61 Dumont N, Arteaga C L. Transforming growth factor-beta and breast cancer: tumor promoting effects of transforming growth factor-beta.  Breast Cancer Res. 2000;  2 125-132
    CrossrefPubMedGoogle Scholar
  • 62 Murphy-Ullrich J E, Schultz-Cherry S, Hook M. Transforming growth factor-beta complexes with thrombospondin.  Mol Biol Cell. 1992;  3 181-188
    PubMedGoogle Scholar
  • 63 Taraboletti G, Belotti D, Borsotti P et al.. The 140-kilodalton antiangiogenic fragment of thrombospondin-1 binds to basic fibroblast growth factor.  Cell Growth Differ. 1997;  8 471-479
    PubMedGoogle Scholar
  • 64 Majack R A, Goodman L V, Dixit V M. Cell surface thrombospondin is functionally essential for vascular smooth muscle cell proliferation.  J Cell Biol. 1988;  106 415-422
    CrossrefPubMedGoogle Scholar
  • 65 Hogg P J, Hotchkiss K A, Jimenez B M, Stathakis P, Chesterman C N. Interaction of platelet-derived growth factor with thrombospondin 1.  Biochem J. 1997;  326(pt 3) 709-716
    CrossrefPubMedGoogle Scholar
  • 66 Krishnaswami S, Ly Q P, Rothman V L, Tuszynski G P. Thrombospondin-1 promotes proliferative healing through stabilization of PDGF.  J Surg Res. 2002;  107 124-130
    PubMedGoogle Scholar
  • 67 Ichii T, Koyama H, Tanaka S et al.. Thrombospondin-1 mediates smooth muscle cell proliferation induced by interaction with human platelets.  Arterioscler Thromb Vasc Biol. 2002;  22 1286-1292
    PubMedGoogle Scholar
  • 68 Lamszus K, Joseph A, Jin L et al.. Scatter factor binds to thrombospondin and other extracellular matrix components.  Am J Pathol. 1996;  149 805-819
    PubMedGoogle Scholar
  • 69 Goicoechea S, Orr A W, Pallero M A, Eggleton P, Murphy-Ullrich J E. Thrombospondin mediates focal adhesion disassembly through interactions with cell surface calreticulin.  J Biol Chem. 2000;  275 36358-36368
    CrossrefPubMedGoogle Scholar
  • 70 Goicoechea S, Pallero M A, Eggleton P, Michalak M, Murphy-Ullrich J E. The anti-adhesive activity of thrombospondin is mediated by the N-terminal domain of cell surface calreticulin.  J Biol Chem. 2002;  277 37219-37228
    CrossrefPubMedGoogle Scholar
  • 71 Wong S Y, Purdie A T, Han P. Thrombospondin and other possible related matrix proteins in malignant and benign breast disease. An immunohistochemical study.  Am J Pathol. 1992;  140 1473-1482
    PubMedGoogle Scholar
  • 72 Wakiyama T, Shinohara T, Shirakusa T, John A S, Tuszynski G P. The localization of thrombospondin-1 (TSP-1), cysteine-serine-valine-threonine-cysteine-glycine (CSVTCG) TSP receptor, and matrix metalloproteinase-9 (MMP-9) in colorectal cancer.  Histol Histopathol. 2001;  16 345-351
    PubMedGoogle Scholar
  • 73 Rice A J, Steward M A, Quinn C M. Thrombospondin 1 protein expression relates to good prognostic indices in ductal carcinoma in situ of the breast.  J Clin Pathol. 2002;  55 921-925
    CrossrefPubMedGoogle Scholar
  • 74 Alvarez A A, Axelrod J R, Whitaker R S et al.. Thrombospondin-1 expression in epithelial ovarian carcinoma: association with p53 status, tumor angiogenesis, and survival in platinum-treated patients.  Gynecol Oncol. 2001;  82 273-278
    CrossrefPubMedGoogle Scholar
  • 75 Tuszynski G P, Rothman V L, Deutch A H, Hamilton B K, Eyal J. Biological activities of peptides and peptide analogues derived from common sequences present in thrombospondin, properdin, and malarial proteins.  J Cell Biol. 1992;  116 209-217
    CrossrefPubMedGoogle Scholar
  • 76 Tuszynski G P, Rothman V L, Papale M, Hamilton B K, Eyal J. Identification and characterization of a tumor cell receptor for CSVTCG, a thrombospondin adhesive domain.  J Cell Biol. 1993;  120 513-521
    CrossrefPubMedGoogle Scholar
  • 77 Bogdanov Jr A, Marecos E, Cheng H C et al.. Treatment of experimental brain tumors with trombospondin-1 derived peptides: an in vivo imaging study.  Neoplasia. 1999;  1 438-445
    CrossrefPubMedGoogle Scholar

George P TuszynskiPh.D. 

Center for Neurovirology and Cancer Biology, Temple University

1900 North 12th Street, Philadelphia, PA 19122

Email: gpt@temple.edu